Related Experiment Video
Updated: May 23, 2026
11:10
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
Immobilized sialyloligo-macroligand and its protein binding specificity
Satya Nandana Narla1, Xue-Long Sun
1Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115, USA.
Biomacromolecules
|April 24, 2012
Summary
We developed a chemoenzymatic method to create functional glycopolymers for glycoarrays and biosensors. These tools mimic natural carbohydrate presentation for improved virus diagnosis and drug screening.
Area of Science:
- Carbohydrate Chemistry
- Polymer Science
- Biotechnology
Background:
- Sialyllactose-containing glycopolymers are crucial for understanding biological interactions.
- Developing efficient synthesis and immobilization methods is key for glycoarray and biosensor applications.
Purpose of the Study:
- To chemoenzymatically synthesize chain-end functionalized sialyllactose-containing glycopolymers.
- To create oriented glycoarrays and surface plasmon resonance (SPR)-based biosensors for biological applications.
Main Methods:
- Cyanoxyl-mediated free radical polymerization to synthesize a lactose-containing glycopolymer.
- Enzymatic α2,3- and α2,6-sialylation to functionalize the glycopolymer.
- Isourea bond formation for immobilizing glycopolymers onto glass slides and SPR chips.
Main Results:
- Achieved quantitative α2,3- and α2,6-sialylation confirmed by (1)H NMR.
- Demonstrated specific lectin binding on glycoarrays and SPR biosensors.
- Showed specific binding of influenza viral hemagglutinins (HA) to the SPR biosensor.
Conclusions:
- The developed method provides a versatile platform for creating functional glycopolymers.
- The resulting glycoarrays and SPR biosensors mimic natural 3D carbohydrate presentation.
- These tools offer high-throughput applications for virus diagnosis and antiviral drug screening.
Related Concept Videos
02:40Ligand Binding Sites
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
00:49Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
01:30Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
01:29Drug Distribution: Plasma Protein Binding
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...